As the J.P. Morgan Healthcare Conference entered the final day for 2020, a few topics rose to the top as trending, including the relative lack of big deals.

Prescription drug errors are a leading source of harm in health care, resulting in substantial morbidity, mortality and health care costs estimated at more than $20 billion annually in the United States.

HVH Precision Analytics announced a proprietary artificial intelligence and machine learning platform used to predict patterns and provide insights to help make informed critical business decisions.

AstraZeneca topped the first annual Pharmaceutical Invention Index, released by IDEA Pharma.

Researchers at the University of Strathclyde in Glasgow, Scotland, potentially developed a blood test for brain cancer using high-throughput attenuated total reflection (ATR)-Fourier transform infrared (FTIR) spectroscopy with machine learning.

AstraZeneca struck a deal to use Schrödinger’s advanced computing platform to help accelerate drug discovery efforts.

LabTwin GmbH, the world’s first voice and AI-powered digital lab assistant, announced the company’s new open API that will connect scientists with data sources both inside and outside of the lab.

Gilead Sciences Inc. will partner with privately held insitro to develop therapies for a fatty liver disease called NASH.

Oxford BioMedica announced a two-year research-and-development collaboration with Microsoft Research. The goal is to improve the yield and quality of next-generation gene therapy vectors – typically viruses – using artificial intelligence (AI) and machine learning.

Machine learning and artificial intelligence (AI) may resoundingly improve on traditional methods of drug development by biopharmaceutical companies.